BBOT Company Profile and Key Details
NASDAQ : BBOT
BridgeBio Oncology Therapeutics
$4.88
-0.17-3.37%
At Close 4:00 PMPrice Chart
Stock Price Today
BridgeBio Oncology Therapeutics Inc. (BBOT) stock declined over -3.37%, trading at $4.88 on NASDAQ, down from the previous close of $5.05. The stock opened at $5.01, fluctuating between $4.74 and $5.02 in the recent session.
Stock Snapshot
5.05
Prev. Close
390.92M
Market Cap
4.735
Day Low
-2.43
P/E Ratio
-2.00705
EPS (TTM)
N/A
Cash Flow per Share
5.01
Open
80.11M
Number of Shares
5.015
Day High
0.57%
Free Float in %
N/A
Book Value
629K
Volume
Relevant Articles
SEC Fillings
Current Report (8-k)
| Filing Date | Accepted Date | |
|---|---|---|
Annual Report (10-k)
| Filing Date | Accepted Date | |
|---|---|---|
Stock Price History Chart
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | 5.01 | 5.01 | 4.72 | 4.88 | 629K |
| Sep 14, 2026 | 4.91 | 5.18 | 4.85 | 5.05 | 955.99K |
| Sep 11, 2026 | 5.53 | 5.62 | 4.90 | 4.95 | 1.63M |
| Sep 10, 2026 | 6.79 | 6.79 | 5.48 | 5.52 | 2.79M |
| Sep 09, 2026 | 8.86 | 8.86 | 6.30 | 6.76 | 1.49M |
| Sep 08, 2026 | 8.88 | 9.05 | 8.78 | 8.86 | 152.34K |
| Sep 04, 2026 | 8.80 | 9.06 | 8.65 | 8.98 | 117.62K |
| Sep 03, 2026 | 8.93 | 9.04 | 8.66 | 8.90 | 139.21K |
| Sep 02, 2026 | 8.81 | 9.19 | 8.73 | 8.89 | 238.88K |
| Sep 01, 2026 | 8.70 | 8.90 | 8.54 | 8.82 | 145.62K |
| Aug 31, 2026 | 8.72 | 9.20 | 8.41 | 8.80 | 476.04K |
| Aug 28, 2026 | 9.16 | 9.16 | 8.69 | 8.74 | 195.03K |
| Aug 27, 2026 | 9.19 | 9.32 | 9.06 | 9.18 | 385.27K |
| Aug 26, 2026 | 9.36 | 9.47 | 9.04 | 9.26 | 247.15K |
| Aug 25, 2026 | 9.24 | 9.47 | 9.18 | 9.37 | 197.62K |
| Aug 24, 2026 | 9.10 | 9.36 | 8.80 | 9.14 | 338.52K |
| Aug 21, 2026 | 9.19 | 9.44 | 9.03 | 9.08 | 170.95K |
| Aug 20, 2026 | 9.55 | 9.78 | 9.08 | 9.08 | 202.24K |
| Aug 19, 2026 | 9.16 | 9.72 | 9.14 | 9.60 | 414.3K |
| Aug 18, 2026 | 9.02 | 9.13 | 8.82 | 8.95 | 446.87K |
Contact Details
About Company
BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients with KRASG12C mutant non-small cell lung cancer; and BBO-11818, an orally bioavailable small molecule pan-KRAS inhibitor, which is in Phase I clinical trial for the treatment of patients with KRAS G12D and KRAS G12V cell-derived xenograft models. It is also involved in the development of BBO-10203, an orally bioavailable small molecule, which is in Phase I clinical trial for the treatment of patients with HER2+ breast cancer, HR+/HER2- breast cancer, KRAS mutant colorectal cancer, and KRAS mutant non-small cell lung cancer; and precision oncology assets for patients with tumors. The company was incorporated in 2016 is headquartered in South San Francisco, California.
Company Information
| Employees | 88 |
| Beta | 0.39 |
| Sales or Revenue | N/A |
| 5Y Sales Change% | N/A |
| Fiscal Year Ends | N/A |
| Sector | Healthcare |
| Industry | Biotechnology |
Stock Peers
ARGX
-10.78-1.09%
argenx SE$979.76REGN-19.63-2.47%
Regeneron Pharmaceuticals, Inc.$774.11MDGL-16.8-3.11%
Madrigal Pharmaceuticals, Inc.$523.26VRTX-4.88-0.94%
Vertex Pharmaceuticals Incorporated$514.63UTHR-2.35-0.47%
United Therapeutics Corporation$500.35ONC-7.33-2.07%
BeOne Medicines AG$346.50KRYS-3.35-0.99%
Krystal Biotech, Inc.$336.68KRTX0.09+0.03%
Karuna Therapeutics, Inc.$329.83PRAX-17.65-5.34%
Praxis Precision Medicines, Inc.$312.90LGND-3.67-1.31%
Ligand Pharmaceuticals Incorporated$276.98Company Overview
BridgeBio Oncology Therapeutics Inc. (NASDAQ:BBOT) closed at $4.88 USD, losing -$0.17 (-3.37%) from the previous close of $5.05. The stock is currently within 5% of its 52-week low $4.72 and $14.87. With a market capitalization of about $390.92 million, BridgeBio Oncology Therapeutics Inc. is classified as a small-cap and shows lower-than-market volatility (beta ~0.39). Key stats such as the average daily volume over the past year has been around 461.15 thousand shares, in line with its 52-week average. Headquartered in South San Francisco, CA, BridgeBio Oncology Therapeutics Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Pedro J. Beltran, the company employs approximately 88 people and listed since August 12, 2025. BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States.
Technical Performance
Short-term trend indicators are mixed aligned (SMA20 -6.56%, SMA50 -12.25%, SMA200 -8.8%). The stock’s 14-day RSI is 41.26 (neutral), while the ATR of 0.81 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -31.07% below its high and over 20.59% above its low. Average 10-day trading volume of 1.27 million shares is significantly above the 3-month average of 461.78 thousand, indicating heightened recent market interest.
Dividend & Fair Value
BridgeBio Oncology Therapeutics Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $11.91. This means the shares are trading below this model’s fair value.
Earnings & Analyst Outlook
Analyst sentiment is bullish. Analyst rating data shows there are 11 Strong Buy ratings, 5 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $39.00 to $20.00. The high target offers 699.18% upside. The low target suggests 309.84% downside. The mean target is $24.94. This offers 411.07% upside. BridgeBio Oncology Therapeutics Inc. earnings surprise history is a mixed track record. The quarter that ended August 11, 2026, missed forecasts by 24.81%. The prior quarter beat by 2.76%. Over the last six quarters, Apple has recorded several small beats. These include 169.63% in November 12, 2025.
Shareholding & Insider Activity
BridgeBio Oncology Therapeutics Inc. has 80.17 million shares outstanding. The public float is 35.81 million shares, elevated short interest at 20.46% of float. This equals 5.83 million shares. The short ratio is 15.97 days. Institutional investors hold 94.53% of the float. Insiders own 27.11%.
Frequently Asked Questions
What is the current BridgeBio Oncology Therapeutics Inc. (BBOT) stock price?
BridgeBio Oncology Therapeutics Inc. (NASDAQ: BBOT) stock price is $4.88 in the last trading session. During the trading session, BBOT stock reached the peak price of $5.02 while $4.74 was the lowest point it dropped to. The percentage change in BBOT stock occurred in the recent session was -3.37% while the dollar amount for the price change in BBOT stock was - $0.17.
BBOT's industry and sector of operation?
The NASDAQ listed BBOT is part of Biotechnology industry that operates in the broader Healthcare sector. BridgeBio Oncology Therapeutics Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Who are the executives of BBOT?
No Data
How BBOT did perform over past 52-week?
BBOT's closing price is 3.39% higher than its 52-week low of $4.72 where as its distance from 52-week high of $14.87 is -67.18%.
How many employees does BBOT have?
Number of BBOT employees currently stands at 88.
Link for BBOT official website?
Official Website of BBOT is: https://bbotx.com
How do I contact BBOT?
BBOT could be contacted at phone 650 405 4770 and can also be accessed through its website. BBOT operates from 256 E. Grand Avenue, South San Francisco, CA 94080, United States.
How many shares of BBOT are traded daily?
BBOT stock volume for the day was 629K shares. The average number of BBOT shares traded daily for last 3 months was 461.15K.
What is the market cap of BBOT currently?
The market value of BBOT currently stands at $390.92M with its latest stock price at $4.88 and 80.11M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.
© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep